Effects of GLP-1 on Chronic Heart Failure

Effects of Liraglutide on Left Ventricular Function in Chronic Heart Failure Patients With Type 2 Diabetes

The investigators planned to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

Heart failure (HF) is a major cause of morbidity and mortality world wide. Glucagon-like peptide-1 (GLP-1) is an incretin hormone that regulates plasma glucose, and has direct effects on the cardiovascular system. In our previous study, the GLP-1 analogue liraglutide could improve left ventricular function in patients with acute myocardial infarction. However, the effects of GLP-1 on chronic heart failure patients with type 2 diabetes remain unclear. The aim of this study was to evaluate the effects of liraglutide on left ventricular function in chronic heart failure patients with type 2 diabetes.

Inclusion Criteria:

• Chronic heart failure patients with type 2 diabetes (NYHA-class I, II or III) were eligible for the study

Exclusion Criteria:

• CHF (NYHA class IV)
• Type 1 diabetes
• Hospitalisation due to incompensated heart disease within 30 days prior to randomisation
• Myocardial infarction within the past 3 months before screening
• Coronary revascularisation within the past 3 months before screening
• Atrial fibrillation with ventricular frequency >100/min in rest
• ECG suggestive of malignant ventricular arrhythmia
• Prolonged QT-interval (>500 ms)
• Valvular heart disease
• Current myocardial or pericardial infection
• Obstructive hypertrophic cardiomyopathy
• Cancer unless in complete remission for ≥5 years
• Acute pancreatitis
• Compromised kidney function (eGFR <30 mL/min), dialysis or kidney transplantation
• History of thyroidea adenoma or carcinoma